Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics's stock price increased by 65.24% over the prior year as of April 7, 2026, but decreased by 3.04% in the past month. Key events include strong Q4 and full-year 2025 financial results, with significant revenue growth for ZORYVE and positive topline data from the INTEGUMENT-INFANT Phase 2 trial. The company also reported Q3 2025 financial results with increased revenue due to demand and the launch of ZORYVE foam. ZORYVE cream 0.05% received FDA approval for atopic dermatitis in children. Insider holdings decreased by 8.35% between December 23, 2025, and March 23, 2026, with notable purchases and sales by executives and directors.

Arcutis Biotherapeutics expects some seasonality in the demand for its products, particularly for ZORYVE in atopic dermatitis, due to factors such as deductible resets and changes in patient insurance plans. Despite these typical seasonal headwinds, the company has noted strong growth in ZORYVE demand across its portfolio.

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Their lead product is ZORYVE (roflumilast), a PDE4 inhibitor approved for topical treatment of plaque psoriasis, atopic dermatitis, plaque psoriasis of the scalp and body, and seborrheic dermatitis. The company's pipeline includes product candidates like ARQ-255 for alopecia areata, ARQ-252 for chronic hand eczema and vitiligo, and ARQ-234 for atopic dermatitis.

Arcutis Biotherapeutics, Inc. is headquartered in Westlake Village, California, United States, with its primary operational and commercial footprint within the United States.

Arcutis Biotherapeutics has cultivated a positive brand reputation through its commitment to innovation in medical dermatology and the successful development and commercialization of ZORYVE. The company is recognized for focusing on unmet needs in immune-mediated dermatological diseases and for developing differentiated topical and systemic treatments. Successful product launches, positive clinical trial results, FDA approvals, and strategic priorities have positively affected its reputation.

Arcutis Biotherapeutics, Inc. has a mixed ownership structure, with institutional investors holding approximately 68.61% to 91.06% of the stock. Company executives and insiders hold approximately 9.34% to 9.41% of the shares. Major institutional owners include Suvretta Capital Management, Llc, Frazier Life Sciences Management, L.P., and BlackRock, Inc. Top individual insider holders include Life Sciences Viii, L.P. Frazier, Bhaskar Chaudhuri, and Todd Watanabe.